Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Conditions
Interventions
Intervention1: Continous Infusion of Terlipressin: Administered as a continuous infusion at 4 mg per 24 hours. After 12 hours, if the hepatic venous pressure gradient (HVPG) does not show a reduction
Sponsors
Institute of Liver and Biliary Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult patients (age more than equals to 18 years) diagnosed with ACLF presenting with due to esophageal varices bleeding.
Exclusion criteria
Exclusion criteria: 1. History of coronary heart disease or ventricular arrhythmia, 2. Stroke or transient ischemic attack, 3. Bronchial asthma, 4. Epilepsy, 5. Pregnancy, 6. Rebleeding. 7. HCC 8. Gastric variceal bleed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HVPG responder at 12-24 hours in both armsTimepoint: 12-24 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| Failure to control hemostasisTimepoint: 5 days;Terlipressin-related complications within 5 days i.e. safety of the drugTimepoint: 5 days;Number of blood transfusions at 5 daysTimepoint: 5 days;Rebleed within 42 day.Timepoint: 42 days;Incidence of post-bleed AKI within 5 days.Timepoint: 5 days;6 weeks mortality in both groupsTimepoint: 6 weeks | — |
Countries
India
Contacts
Public ContactDr Vinod Arora
Institute of Liver and Biliary Sciences
Outcome results
None listed